Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.

Business Strategies M & A Deals

New Drugs Shine But Biosimilars Blunt Roche Revenue Rise

MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.

Biosimilars Sales & Earnings ImmunoOncology

Brexit Ambiguity A Top Priority For Bayer's New UK & Ireland CEO

Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.

Brexit Business Strategies Market Access
Advertisement

Publisher's Spotlight: Informa’s CARE Awards Open For Nominations

Enter your clinical research team, novel trial design, outstanding results and more for Informa Pharma Intelligence’s 2018 Clinical and Research Excellence (CARE) Awards.

Clinical Trials Innovation Research and Development Strategies


 Recent Tweets from Scrip


Commercial Explore this Topic

Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.

Deals ImmunoOncology Cancer

$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases

Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.

Financing Deals Infectious Diseases

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.

Approvals Cancer

Anthem In-House PBM Will Rely On CVS But Retain Formulary Control

Hybrid approach to pharmacy benefit management expected to save insurer $4bn annually after Anthem ends its relationship with Express Scripts in 2020. Plans include "going out to the market and competing with the freestanding PBMs."

Pharmacy Benefit Management Private Payers

If Orexigen Disappears, Who's Left In The Obesity Market?

Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.

Business Strategies Commercial

UK R&D Centre for Antimicrobial Resistance Goes Into Battle

The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.

Business Strategies Commercial

Silence Seeks Share Of Alnylam RNAi Success In Legal Action

The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.

Intellectual Property Commercial

Lynparza Partners AZ And Merck & Co Target US Breast Cancer Market

AstraZeneca and Merck & Co's strategic collaboration on the development of olaparib and other anticancers has the US breast cancer sector in its sights, with approval of a US sNDA in the indication expected in early 2018.

Approvals Cancer

Policy & Regulation Explore this Topic

Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects

Sponsor's proposal for a label warning, but not a black box, on retinopathy risk with the once-weekly GLP-1 agonist finds support from a US FDA advisory committee, which overwhelming endorsed approval for treatment of type 2 diabetes on the basis of robust glycemic control efficacy data and a strong cardiovascular safety profile.

Advisory Committees Drug Review Metabolic Disorders

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.

Approvals Cancer

Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries

Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.

Metabolic Disorders Advisory Committees

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'

Intellectual Property Legal Issues

Research & Development Explore this Topic

UniQure Hemophilia B Gene Therapy Changes Ignite A Race To Market

UniQure is switching the gene therapy it plans to move into a pivotal trial in hemophilia B patients because the new version could have clinical benefits. Regulatory agencies in the US and Europe have given the change a green light, and uniQure plans to begin a pivotal trial in 2018.

Clinical Trials Regenerative Medicine Research & Development

Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC

Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.

Research & Development Clinical Trials

Ignyta's Entrectinib Data Sets Prospects Alight

Interim data from STARTRK-2 study point to best-in-class status for Ignyta's entrectinib in a subset of non-small cell lung cancer patients – posing a threat to Xalkori. US NDA filings are set for 2018.

Clinical Trials Research & Development

Momentum For ViroMed's Gene Therapy After ‘Exceptional’ Trial Go-Ahead In China

China FDA has granted earlier-than-expected approval to begin a Phase III clinical trial of ViroMed's gene therapy VM202. Successful trials in China are expected to support global commercialization of the first-in-class therapy for cardiovascular and neurological diseases, which is also in late-stage clinical development in the US.

Research & Development Clinical Trials
UsernamePublicRestriction

Register

Advertisement